Effect of pre-exchange albumin infusion on neonatal hyperbilirubinaemia and long-term developmental outcomes

To determine the effects of pre-exchange albumin infusion on the frequency and severity of hyperbilirubinaemia, long-term neurodevelopmental outcomes, complications of exchange transfusion; and to determine the adverse effects of pre-exchange albumin infusion in infants with hyperbilirubinaemia requiring exchange transfusion.

Primary comparisons
  1. Pre-exchange albumin infusion plus exchange transfusion versus exchange transfusion alone. Phototherapy may or may not be given in the trials.
  2. Subgroup analyses based on gestational age (term infant (≥ 37 weeks) versus preterm infant (< 37 weeks)), causes of jaundice (haemolytic disease versus non-haemolytic disease), dose of albumin, volume of exchange transfusion, and associated medical therapy (phototherapy, metalloporphyrins, barbiturates, charcoal, cholestyramine, clofibrate, D-penicillamine, glycerin, manna, riboflavin, traditional Chinese medicine, homeopathy and agar, which are used before albumin infusion).

This is a protocol.